Search the Newsreel

Earnings Flash (MANE) Veradermics Posts Q2 Net Loss $23.5M, vs. FactSet Est of $26.8M Loss

Dermapharm: EBITDA steigt, Prognose für 2026 bestätigt

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape …

Veradermics (MANE) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Stock Decline - Strong Earnings Momentum

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

Dermata Therapeutics (NASDAQ:DRMA) announced that its first direct-to-consumer skincare product, Tome Foundational Treatment, will launch on August 25, 2026. This product, featuring proprietary Bioneedle™ technology, marks Dermata's strategic shift to a consumer-focused skincare company, offering a professional-grade skin renewal treatment for at-home use. The …

Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Dermata Therapeutics Inc (DRMA) is projected to report a loss of 55 cents per share, according to an earnings preview. The article, sourced from Reuters, indicates that this financial forecast is available through TradingView News.

Journey Medical Corp (DERM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Journey Medical Corp (DERM) has an earnings forecast score of 8.00, ranking 58th in the Pharmaceuticals industry, with an average price target of $13.00 from analysts. Four analysts currently rate DERM as a "Buy," anticipating a significant upside. The company's expected revenue for the …

FMR LLC discloses 7.6% Veradermics Inc. (MANE) ownership in Schedule 13G

FMR LLC and Abigail P. Johnson have disclosed a 7.6% passive ownership stake in Veradermics Inc. (MANE) common stock through a Schedule 13G filing. The filing indicates beneficial ownership of 3,193,181 shares as of June 30, 2026, with FMR LLC holding sole voting and …

Price to sales forward of Veradermics, Incorporated – NYSE:MANE

This article provides a brief financial overview for Veradermics, Incorporated (NYSE: MANE), specifically focusing on its price-to-sales forward metric. It appears to be a snapshot from a financial data platform, indicating that the market is closed and no trades have occurred for the company. …

Dermata to launch first consumer skincare product Aug. 25 By Investing.com

Dermata Therapeutics (NASDAQ:DRMA) announced the upcoming launch of its first direct-to-consumer skincare product, Tome Foundational Treatment, on August 25, 2026. This launch marks a strategic shift for the company from developing prescription dermatologic products to focusing on consumer skincare. The Tome Foundational Treatment is …

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Journey Medical Corporation (Nasdaq: DERM) announced it will release its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results …

Nine FDA-approved dermatology drugs: Journey Medical sets Aug. 12 call

Journey Medical Corporation (Nasdaq: DERM) announced it will release its second-quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET to discuss …

Dermata’s First Consumer Brand Wants to Function as ‘Microneedling Lite’

Dermata Therapeutics is launching its first consumer skincare brand, Tome, which features a "microneedling lite" weekly treatment. The product, priced at $178 for four treatments, uses Spongilla lacustris spicules to accelerate cell turnover and address various skin concerns. Tome plans to target experienced skincare …

Journey Medical (DERM) Expected to Post Earnings on Tuesday

Journey Medical (NASDAQ:DERM) is anticipated to report its Q2 2026 earnings after the market closes on Tuesday, August 11th. Analysts predict a loss of $0.01 per share and revenue of $18.3590 million. The company's previous quarter missed EPS estimates but exceeded revenue expectations.

Veradermics (MANE) Positioned to Disrupt Hair Loss Market

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Veradermics Falls 4.4% as Lock-Up Expiry Appears to Weigh on Shares

Veradermics (MANE) shares dropped 4.4% due to the expiration of post-IPO lock-up restrictions, allowing 20,000,170 shares to become eligible for resale. This decline is attributed to share-supply pressure rather than negative clinical news, as the company recently reported positive Phase 2 data and is …

Journey Medical (NASDAQ:DERM) Stock Price Down 1.2% - What's Next?

Journey Medical (NASDAQ:DERM) saw its stock price decline by 1.2% to $6.37, with a significantly lower trading volume compared to its average. The company's stock is currently below its 50-day and 200-day moving averages, and analyst sentiment is mixed, resulting in a consensus "Hold" …

Vanguard Capital Management (DERM) discloses 774,556 Journey Medical shares in 13G/A

Vanguard Capital Management has filed an amended Schedule 13G/A, disclosing beneficial ownership of 774,556 shares of Journey Medical Corp common stock, which represents 3.59% of the class. Vanguard has sole voting power over 99,371 shares and sole dispositive power over all 774,556 shares. The …

Journey Medical Corp (DERM) Cash Flow

This article provides a detailed cash flow statement for Journey Medical Corp (DERM), presenting quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics such as net income from continuing operations, changes in working capital, capital expenditures, and net …

Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook

Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to "overweight" from "equal-weight" and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth forecasts for the company's Nemluvio drug and injectable aesthetics business after the Swiss dermatology …

Journey Medical Corp (DERM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Journey Medical Corp (DERM), detailing its price momentum score, support and resistance levels, and indicator and moving average readings. As of August 3, 2026, DERM had a price momentum score of 4.06, with the stock trading between …

Dermata Therapeutics, Inc. Revenue Breakdown – NASDAQ:DRMA

This article provides a financial overview of Dermata Therapeutics, Inc. (NASDAQ:DRMA) on TradingView. It indicates that the market was closed with no trades. The content also lists various financial and analytical tools available on the platform, alongside information about the company and community features.

Journey Medical Corp (DERM) Institutional Confidence

Journey Medical Corp (DERM) has an institutional shareholding score of 5.00, ranking 72nd out of 156 in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 93.34% quarter-over-quarter to 56.62%. The largest institutional shareholder is Bill Nygren from OAKMX, holding 1.67 million shares, …

14,570,076 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026.

Approximately 14.57 million common shares of Veradermics, Incorporated are under a lock-up agreement that concludes on July 29, 2026. This 91-day lock-up period, which began on April 29, 2026, prevents the company's directors, executive officers, and certain affiliates from selling or transferring these shares …

DRMA|Dermata Therapeutics Inc|Price:1.290|Chg%:-0.030

This article provides a detailed explanation of TradingKey's stock scoring methodology for Dermata Therapeutics Inc (DRMA), covering financial health, company valuation, earnings forecasts, price momentum, institutional confidence, and risk management. It notes that a stock score is not yet available for DRMA due to …

Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Dermata Therapeutics Inc (DRMA), including its stock price, market cap, and links to financial data and analysis tools on TradingKey. It notes that key valuation metrics like P/E, P/B, and P/CF ratios have not yet been disclosed …

DERM|Journey Medical Corp|Price:6.360|Chg%:+0.170

This article provides a detailed profile of Journey Medical Corporation (DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological products. It covers the company's background, business scope, key products like Qbrexza and Accutane, financial data including market capitalization, and lists key executives along with …

Journey Medical Corp (DERM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Journey Medical Corp (DERM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Journey Medical Corp's (DERM) shareholder structure, listing major individual and institutional holders, their proportion of shares, and recent changes in holdings. It also categorizes shareholders by type (e.g., Hedge Fund, Individual Investor) and includes information on institutional …

Journey Medical Corp (DERM) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Journey Medical Corp (DERM)'s dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article primarily functions as a …

Veradermics, Incorporated's Lock-Up Period Set To End on August 3rd (NYSE:MANE)

Veradermics, Inc. (NYSE: MANE) will see its IPO lock-up period expire on August 3rd, potentially allowing major shareholders and insiders to sell their shares. The company, which focuses on dermatological treatments, including pattern hair loss, issued 15.1 million shares at $17 each in February. …

TradingKey

This article presents the quarterly and annual cash flow statements for Dermata Therapeutics Inc (DRMA), detailing operating, investing, and financing cash flows from FY2020Q1 to FY2026Q1. It provides a financial summary of the company's performance, including net income from continuing operations and changes in …

Dermata Therapeutics, Inc. Revenue Breakdown – BOATS:DRMAW

This article provides a financial overview of Dermata Therapeutics, Inc. (DRMAW) on TradingView, focusing on its revenue breakdown. It indicates that no trade data was available at the time of publication, suggesting the market was closed or trading was halted. The page acts as …

Veradermics, Incorporated Revenue Breakdown – NYSE:MANE

This article provides details on Veradermics, Incorporated (NYSE: MANE) financials, including an overview of statements, statistics, dividends, earnings, and segments. It highlights top segments and regional performance by source and country, indicating that the data is provided by ICE Data Services and FactSet. The …

Journey Medical Corp (DERM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Journey Medical Corp (DERM), detailing its current risk score, beta value, and various volatility and return metrics. The company's risk assessment score is 3.91, ranking 93 out of 155 in the Pharmaceuticals industry, with a beta of …

Journey Medical Corporation Revenue Breakdown – NASDAQ:DERM